demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 (hospitalized or not)
neutralizing antibody
casirivimab/imdevimab (Ronapreve) Wei

1 studies excluded by filtering options 2

5570 CT-P59 1.2, 2020 210excludedrisk of bias not avaialble